Smart science to improve lives™

Croda successfully completes acquisition of Solus Biotech

4 July 2023: Croda International Plc (‘Croda’) today confirms that, following receipt of unconditional approval from the South Korean regulatory authorities, it has now successfully completed the acquisition of Solus Biotech, a global leader in premium, biotechnology-derived active ingredients for beauty care and pharmaceuticals.

This follows the announcement on 6 February 2023 that Croda had reached an agreement to acquire Solus Biotech.


6 Feb 2023: Croda International Plc (‘Croda’) announces that it has agreed to acquire Solus Biotech (‘Solus’), a global leader in premium, biotechnology-derived beauty actives, from Solus Advanced Materials for a total consideration of KRW350bn (approximately £232m) on a debt-free, cash-free basis. The acquisition provides access to Solus’ existing biotech-derived ceramide and phospholipid technologies, and its emerging capabilities in natural retinol.  This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments. Located in South Korea, Solus expands Croda’s Asian manufacturing capability and will create a new biotechnology R&D hub in the region.  

Solus is a leading supplier of naturally derived powder ceramides, a high-growth global market with further potential to extend into formulated ceramides. The number of new personal care products containing ceramides has doubled over the last five years, principally for skin care but increasingly for hair care formulations. Access to Croda’s formulation capabilities will accelerate development of Solus’ formulated ceramides to create even greater value for our customers globally and address exciting, formulated ceramide demand.

Solus also brings a portfolio of phospholipids, spanning pharmaceutical applications and beauty care. These naturally derived phospholipids are produced at a GMP plant and can be used as delivery systems for pharmaceutical actives and cosmetics. This will strengthen our Pharma presence in Asia and enable collaborative R&D with Croda’s Avanti business for the supply of lipid systems for drug delivery. In addition, Solus is developing biotech-derived retinol, which is an exciting, sustainable alternative to synthetically derived retinol.  
Solus’ growth will be accelerated by Croda’s ownership through access to our technical and innovation capabilities, particularly in formulation, and by accessing our global selling network. The acquisition will give Croda greater ability to serve luxury beauty customers in Asia and globally, and the opportunity to accelerate delivery of Avanti’s pharma product pipeline.

Commenting, Steve Foots, Chief Executive of Croda, said:

“This is a strategic bullseye for Croda, consolidating our position as a global leader in supplying sustainable, natural actives for personal care across three critical technology platforms of peptides, ceramides and retinol. It significantly enhances our sustainable biotechnology capabilities and adds a North Asia manufacturing and innovation facility, providing a springboard to premium markets in Asia and beyond. I am especially excited about their brilliant technology, with Solus bringing rich IP and proprietary know-how that we will be able to deliver to customers globally.” 

The acquisition is subject to regulatory approval. 

Croda will report its financial results for 2022 on 28 February 2023.    

About Solus Biotech

Solus Biotech has more than 30 years’ experience in biotechnology and fermentation.  The business generated approximately KRW43bn (c.£28m) of sales in 2022. It employs 95 people in South Korea at its R&D centre in Bundag near Seoul and its production centre in Iksan.

Further information
For enquiries contact:
Investors: David Bishop, Croda +44 7823 874428
Press: Charlie Armitstead, Teneo +44 7703 330269

For more information regarding Solus Biotech within our sectors, please follow the links below:


Personal Care

white cream texture on pink background

Portfolio expansion: Tech & Nature combine for biotech success

Learn more about our range of biotechnology-derived, bio-based ceramides, sphingolipids and phospholipids, and the powerful benefits they can deliver to your cosmetic formulations.

We offer high purity, multi-compendial, pharmaceutical excipients for small molecule drug delivery. Our portfolio of high purity excipient products and speciality chemistries solve formulation challenges and enhance drug delivery across a variety of administration routes and dosage forms.

Natural phospholipids

We are specialised in the extraction and purification of phospholipids for pharmaceutical and nutraceutical applications. Using innovative technologies in research and development of phospholipids, we offer a variety of highly purified phosphatidylcholine products originated from soybean and sunflower seed.